指南与共识眼底病与葡萄膜炎

新生血管性年龄相关性黄斑变性中布西珠单抗风险缓解共识:患者选择、评估与治疗

A CONSENSUS ON RISK MITIGATION FOR BROLUCIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Patient Selection, Evaluation, and Treatment.
指南 / 共识 · Retina · 2022-06-13

本共识基于文献综述,针对新生血管性年龄相关性黄斑变性患者使用布西珠单抗时出现的眼内炎症和视网膜血管炎/闭塞事件,提出患者选择、患者教育、注射前炎症评估及炎症及时强化治疗等风险缓解指导,面向全球受众。

要点

  • 使用布西珠单抗前应考虑眼内炎症和视网膜血管闭塞的可能危险因素。
  • 应教育患者了解布西珠单抗后眼内炎症的症状、体征和时间进程。
  • 每次注射布西珠单抗前应评估眼部炎症,发现炎症则不予注射。

核心结论

  • 使用布西珠单抗时,仔细的患者选择、患者教育、炎症评估及对可能炎症的强化治疗均很重要。

研究设计与样本

  • 本共识基于对新生血管性年龄相关性黄斑变性眼注射布西珠单抗后眼内炎症相关不良事件的文献综述制定。

主要发现

  • 布西珠单抗在视网膜积液消退方面高效,并可能提供更长给药间隔。
  • 布西珠单抗与视网膜血管炎和视网膜血管闭塞事件相关,通常伴有其他眼内炎症体征。

关键数值与推荐

  • 给药前应考虑眼内炎症和视网膜血管闭塞的可能危险因素。
  • 应教育患者了解布西珠单抗后眼内炎症的症状、体征和时间进程。
  • 每次注射前应评估眼部炎症,检测到炎症则不予布西珠单抗治疗。
  • 眼内炎症治疗应及时,并特别关注后节。

临床怎么用

  • 临床使用布西珠单抗时,应进行仔细的患者选择、患者教育、炎症评估及对可能炎症的强化治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Brolucizumab has high efficacy in retinal fluid resolution and provides the possibility for longer dosing intervals in the treatment of neovascular age-related macular degeneration. However, brolucizumab has been associated with events of retinal vasculitis and retinal vascular occlusion typically in the presence of other signs of intraocular inflammation (IOI). The purpose of this report is to provide guidance on the use of brolucizumab for neovascular age-related macular degeneration to a global audience. METHODS: A literature review was conducted on adverse events related to IOI after administration of brolucizumab in eyes with neovascular age-related macular degeneration. RESULTS: Possible risk factors for IOI and retinal vascular occlusion after brolucizumab should be considered before administering brolucizumab. Patients who receive brolucizumab should be educated on the symptoms, signs, and time course of IOI after brolucizumab. Before each injection of brolucizumab, physicians should assess the eye for any signs of inflammation and not treat with brolucizumab if inflammation is detected. Treatment of IOI should be prompt and provided with particular attention to the posterior segment. CONCLUSION: Careful patient selection, patient education, assessment for inflammation, and intensive treatment of possible inflammation are important when using brolucizumab in patients with neovascular age-related macular degeneration.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Holz FG, Iida T, Maruko I, et al. A CONSENSUS ON RISK MITIGATION FOR BROLUCIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Patient Selection, Evaluation, and Treatment. Retina. 2022. PMID: 35994582. doi:10.1097/IAE.0000000000003556

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。